<DOC>
	<DOCNO>NCT00583609</DOCNO>
	<brief_summary>To evaluate patient acceptance new PEG3350 dose formulation child currently treat PEG3350 powder treatment constipation .</brief_summary>
	<brief_title>A Pilot Study New PEG3350 Dose Formulation For Use Constipated Children</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Polyethylene glycol 3350</mesh_term>
	<criteria>Male female constipate outpatient age 4 16 Currently take dose PEG 3350 powder maximum 17g per day consistent least 4 week , less 4 week , investigator testifies patient stable Current treatment consider successful define great 2 bowel movement per week accident Are otherwise good health , judge physical examination If female childbearing potential , patient must use oral contraceptive , depot contraceptive , intrauterine device , testify monogamous vasectomized partner , practice abstinence continue duration study In investigator 's judgment , patient guardian mentally competent sign instrument inform consent Patients impacted baseline exam Patients know suspected perforation obstruction Patients history gastric retention , inflammatory bowel disease , bowel resection , colostomy Patients known history organic cause constipation Patients currently use medication know cause constipation ( include opiate , antidepressant , SSRI 's , antimotility agent anticholinergic ) Patients breastfeed , pregnant , intend become pregnant study Female patient childbearing potential refuse pregnancy test Patients , opinion investigator , include study reason , include inability follow study procedure Patients know allergy PEG PEG contain medication Patients , within past 30 day participate investigational clinical study</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>